Fesarius Therapeutics Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its DermiSphere Hydrogel Dermal Regeneration Template (DermiSphere hDRT). This innovative product represents
Although cosmetic treatments have traditionally been geared more towards the adult population, current data reveals a growing trend in cosmetic procedures among pediatric patients. This study aimed to explore the
Research conducted over the years has led to the discovery of the axolotl salamanders (Ambystoma mexicanum) and their remarkable regenerative abilities. These findings offer promising insights for regenerative medicine, skin
In a recent press release, Bristol Myers Squibb announced the positive results of their pivotal Phase 3 trials (POETYK PsA-1 and POETYK PsA-2) evaluating the safety and efficacy of Sotyktu
A recent Medscape report revealed that 24% of respondents use AI tools to analyze medical literature and data. While these AI tools can help organize data and generate content, they
Organon has announced the recent approval of Vtama ® (tapinarof) cream 1% for atopic dermatitis (AD) in adults and children aged 2 years and older. Vtama, an aryl hydrocarbon receptor agonist,
Diet, which plays a critical role in reducing inflammation and improving quality of life, has emerged as a significant factor in managing inflammatory diseases. Concerns, however, continue to mount over
A recent study published in the Journal of Drugs in Dermatology evaluated the safety and efficacy of a novel device combining monopolar radiofrequency (RF) and high-intensity facial electrical stimulation (HIFES)
UCB recently announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX ® (bimekizumab-bkzx) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults. This approval is significant
A recent study published in the Journal of Drugs in Dermatology has highlighted a six-step skincare regimen that improves signs of photoaging. This skincare regimen, called Essential Six (RATIONALE), includes
A recent study published in JAMA Dermatology has evaluated the relationship between precocious puberty and hidradenitis suppurativa (HS) in pediatric patients. Drawing on data from the Explorys databases, the study
The U.S. Food and Drug Administration (FDA) has granted BPGbio a Rare Pediatric Disease Designation for BPM31510T, its investigational treatment for epidermolysis bullosa (EB). This news brings hope to the EB
A recent study published in the Journal of the American Medical Association (JAMA Dermatology) found that patients with newly diagnosed alopecia areata (AA) have a higher prevalence and incidence of
Allergan Aesthetics has announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® Cosmetic for temporary improvement in the appearance of moderate-to-severe vertical bands connecting the jaw and neck
A study conducted in patients with chronic hand eczema (CHE) revealed that topical corticosteroid (TCS) phobia is a great concern, with many fearing future health risks associated with this type
A new phase 2b study is currently underway to evaluate rezpegaldesleukin (REZPEG), an interleukin-2 receptor pathway agonist, for the treatment of severe to very severe alopecia areata (AA). This comes after REZPEG showed
In a study recently presented at the European Academy of Dermatology and Venerology (EADV) Congress 2024, it was revealed that semaglutide has the potential to treat hidradenitis suppurative (HS) in
In a press release from Arcutis Biotherapeutics, Inc., they have announced that the U.S. Food and Drug Administration (FDA) has accepted its sNDA for ZORYVE (roflumilast) foam 0.3% for the
Eli Lilly has announced that EBGLYSS ™ (lebrikizumab-lbkz) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis in adults and children
A team of expert dermatologists recently drafted recommendations for managing atopic dermatitis (AD) to optimize treatment outcomes. They noted that current treat-to-target recommendations for AD “may not include high enough
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
LiVDerm / South Beach Symposium
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2025, LiVDerm. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
